Peregrine Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting

TUSTIN, CA -- (MARKET WIRE) -- 02/28/11 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that data from four studies investigating the company's lead phosphatidylserine (PS)-targeting clinical candidate bavituximab and other PS-targeting antibodies have been accepted for poster presentation at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) to be held in Orlando, Florida, April 2-6, 2011.

Abstracts Accepted at AACR:

Title: Targeting Phosphatidylserine to Improve Androgen Deprivation Therapy of Prostate Cancer<http://ctt.marketwire.com/?release=726219&id=123391&type=1&url=http%3a%2f%2fwww.abstractsonline.com%2fPlan%2fViewAbstract.aspx%3fsKey%3d31c44e8c-f1e8-4ae7-8f2c-bf10be5eabd3%26cKey%3d58a8ca07-86cb-4e15-b00c-22a30956248d%26mKey%3d%257b507D311A-B6EC-436A-BD67-6D14ED39622C%257d> Authors: Yi Yin and Philip E. Thorpe Presentation Time: Sunday, April 3, 2011, 1:00 - 5:00 PM ET Location: Exhibit Hall A4-C, Poster Section 26

Title: Phosphatidylserine-Targeting Antibody Induces Differentiation of Myeloid-Derived Suppressor Cells into M1-Like Macrophages<http://ctt.marketwire.com/?release=726219&id=123394&type=1&url=http%3a%2f%2fwww.abstractsonline.com%2fPlan%2fViewAbstract.aspx%3fsKey%3d71876d0a-c72b-4679-be90-e14ebec61f8b%26cKey%3de9c1c3bd-45c7-4c46-bd61-59207d3008c3%26mKey%3d%257b507D311A-B6EC-436A-BD67-6D14ED39622C%257d> Authors: Xianming Huang, Dan Ye, and Philip E. Thorpe Presentation Time: Tuesday, April 5, 2011, 8:00 AM -12:00 PM ET Location: Exhibit Hall A4-C, Poster Section 31

Title: Phosphatidylserine-Targeting Antibody Combined with Sorafenib has Strong Anti-Tumor Activity against Human Hepatocellular Carcinomas in Mice<http://ctt.marketwire.com/?release=726219&id=123397&type=1&url=http%3a%2f%2fwww.abstractsonline.com%2fPlan%2fViewAbstract.aspx%3fsKey%3dc0a02909-d236-4fd6-bd37-9b9aa299253d%26cKey%3d6f92e581-e293-4dc0-adae-bcee9f42a644%26mKey%3d%257b507D311A-B6EC-436A-BD67-6D14ED39622C%257d> Authors: Xiaoyun Cheng and Philip E. Thorpe Presentation Time: Tuesday, April 5, 2011, 8:00 AM -12:00 PM ET Location: Exhibit Hall A4-C, Poster Section 30

Title: Monitoring Tumor Response to Chemotherapy by In Vivo Real-Time Imaging of Phosphatidylserine Targeting Antibodies<http://ctt.marketwire.com/?release=726219&id=123400&type=1&url=http%3a%2f%2fwww.abstractsonline.com%2fPlan%2fViewAbstract.aspx%3fsKey%3d332b8bc0-e98b-431e-98a8-958dd2dd2d65%26cKey%3d553da1ca-29ce-44e9-a599-a7a58b8b9cc2%26mKey%3d%257b507D311A-B6EC-436A-BD67-6D14ED39622C%257d> Authors: Jian Gong, Linda Him, Christopher Hughes, and Bruce Freimark Presentation Time: Wednesday, April 6, 2011, 8:00 AM -12:00 PM ET Location: Exhibit Hall A4-C, Poster Section 5

For additional information on the 102nd Annual Meeting of the AACR, please visit: http://www.aacr.org/home/scientists/meetings--workshops/aacr-102nd-annual-meeting-2011.aspx<http://ctt.marketwire.com/?release=726219&id=123403&type=1&url=http%3a%2f%2fwww.aacr.org%2fhome%2fscientists%2fmeetings--workshops%2faacr-102nd-annual-meeting-2011.aspx>

About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com<http://ctt.marketwire.com/?release=726219&id=123406&type=1&url=http%3a%2f%2fwww.avidbio.com%2f>), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com<http://ctt.marketwire.com/?release=726219&id=123409&type=1&url=http%3a%2f%2fwww.peregrineinc.com%2f>.

Add to Digg<http://digg.com/submit?phase=2&url=http://www2.marketwire.com/mw/release_html_b1?release_id=726219> Bookmark with del.icio.us<http://del.icio.us/post?v=4&noui&jump=close&url=http://www2.marketwire.com/mw/release_html_b1?release_id=726219> Add to Newsvine<http://www.newsvine.com/_tools/seed&save?u=http://www2.marketwire.com/mw/release_html_b1?release_id=726219>

Peregrine Contact:

Amy Figueroa

Peregrine Pharmaceuticals

(800) 987-8256

info@peregrineinc.com

 

 

Source: Peregrine Pharmaceuticals

 

 

Posted: February 2011

View comments

Hide
(web4)